NetworkNewsWire Newsroom

Monday, November 29, 2021

Insurtech Market Seen as a Major Driver for Big Data and Mobile Tech Innovator FingerMotion Inc. (FNGR)

U.S.-based FingerMotion is a technology innovator focused on smart communication applications in China’s mobile-hungry billion-plus population
The company’s big data services are relatively new in development but already play a significant role in the insurtech industry’s global growth trends
While most of FingerMotion’s revenues are derived from its SMS and MMS products, executives anticipate its big data services will eventually be the company’s largest driver of profits
The insurtech industry has already generated record annual deal-making this year as of the third quarter, outpacing all of 2020 by 48 percent

The insurtech industry has turned 2021 into a record year for business, with deals that have already outpaced all of 2020, by approximately 48 percent, as of the end of the third quarter. Analysts at CBInsights reported insurtechs had raised $10.5 billion across 427 deals by the quarter’s end (https://nnw.fm/ktcJ4).

China communications technology solutions provider FingerMotion (OTCQX: FNGR) plays a part in the trend, inking a big data outlook deal with global insurer Pacific Life early in the year to provide data analytics for Pacific Life’s Re-insurance division, and adding two brands last month that will generate value-add underwriting services by covering mobile consumer device maintenance needs (https://nnw.fm/3dCmC).

FingerMotion’s revenue generator is its mobile device tech services division, which grew 142 percent year-over-year in its Telecommunications Products and Services business sector and 25 percent quarterly in its SMS (texting) and MMS (phone photo, video and audio sharing) sectors as of the most recent financial report in October (https://nnw.fm/2WNty).

But the company anticipates the latest insurtech services will begin to come online early next year and generate new revenue channels in several of China’s provinces.

“This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” CEO Martin Shen stated last month following the financial report. “This quarter was more of a transition to greater profitability as more of our initiatives started contributing to gross margin.”

FingerMotion’s trademarked big data platform, Sapientus, provides the power behind the company’s services, handling over half a million transactions daily for its mobile payment and recharge services.

Although based in the U.S., FingerMotion is focused on the emerging potential of China’s billion-plus population, more than half of which is avid about communications technology to the point of boosting mobile phone subscriptions higher than the country’s actual total population because of the many consumers that use multiple phones.

More than 750 million are described as proximity mobile payment users who pay for goods or services using a mobile phone while visiting in-person at a point-of-sale terminal (https://nnw.fm/7aTvK). Ninety percent of smartphone users in the country want their next device to be 5G-enabled, according to a review by China Internet Watch (https://nnw.fm/kET5l).

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://nnw.fm/FNGR

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating
The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity
Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs
The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders

There is no denying that food is a massive part of the holiday season. With this year’s Thanksgiving celebration kicking off the fall-winter holiday season that will stretch until New Year’s Day, Americans are likely to go all out foodwise, as is tradition. However, for people with eating disorders, the holiday season can constitute a major challenge.

“Holidays may trigger eating disordered behaviors and disordered eating due to the set of stressors that the holidays present; relationship stress, travel, finances, and holiday fatigue are the usual culprits,” explains Cecille Ahrens, a psychotherapist and addiction specialist (https://nnw.fm/N3L5N).

Research suggests that stress pushes people living with eating disorders, including binge-eating disorder (“BED”), toward overeating as they seek to escape from reality and self-awareness. Unfortunately, this means that this year’s holiday season, as with all others before it, may exacerbate the situation among those suffering from eating disorders, causing them to eat even more.

At the same time, the fall-winter holiday season can also adversely impact those suffering from chronic pain. Winter, which comes with changes in temperature, pressure, and moisture, can cause chronic pain patients to experience more aches, stiffness, and a limited range of motion. According to the Pontchartrain Orthopedics & Sports Medicine organization, this heightened achiness considerably increases patients’ pain (https://nnw.fm/pjv7Y). The issue is further compounded by the fact that existing FDA-approved chronic pain drugs have limited efficacy and/or significant side effects.

Fortunately, positive change may be in the offing for people living with these conditions. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company pursuing the development of novel bioscience solutions that aim to address indications with high unmet needs, is leading the next wave of psychedelic drug development with a laser focus on chronic pain, eating disorders, and other unique conditions.

The company has made significant progress as it advances toward the rollout of multiple Phase 2a clinical studies to be conducted in collaboration with the University of Michigan and the University of Florida. The studies will evaluate the safety and preliminary effectiveness of Tryp’s TRP-8802, a non-proprietary 25 mg oral capsule of synthetic psilocybin, for the treatment of fibromyalgia, phantom limb pain syndrome, complex regional pain syndrome, BED, and hypothalamic obesity.

In line with a recent response to its Investigational New Drug (“IND”) application, Tryp will focus enrollment of the initial Phase 2a study on patients with BED. In addition, the company will submit an IND application for a separate Phase 2a study evaluating TRP-8802 with hypothalamic obesity (https://nnw.fm/svCCW).

Earlier in November, Tryp also submitted an IND application to evaluate the safety and preliminary effectiveness of TRP-8802 in a Phase 2a clinical trial involving patients with fibromyalgia, a class of chronic pain. Tryp anticipates initiating this study next year subject to a favorable review of the IND application (https://nnw.fm/0MoeJ).

Tryp has already received IND authorization for a Phase 2a clinical trial in phantom limb pain, a type of chronic pain (https://nnw.fm/HMbf7).

Tryp expects to use data from the multiple Phase 2a studies, as well as various data sets to support the use of TRP-8803, its proprietary psilocybin-based drug product with a novel route of administration, in Phase 2b studies. Eventually, the company intends to commercialize its drug product, potentially easing the challenges and difficulties that eating disorder patients and people suffering from chronic pain face during the holiday seasons.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs

InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials
The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million
Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales
InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders
Preclinical data of INM-088, the company’s cannabinol (“CBN”) formulation for the treatment of glaucoma, show CBN’s effectiveness in reducing cell death in retinal ganglion cells

For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of its programs. And in a business update accompanying the release of its Q1 2022 financial results, the company discussed this momentum in relation to the progress made thus far (https://nnw.fm/fsaqt).

On October 13, InMed closed the previously announced (https://nnw.fm/kMJN3) acquisition of BayMedica Inc., in a transaction that created an industry leader in the manufacture and commercialization of rare cannabinoids. The integrated teams are now working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry.

“For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol(R) CBC (cannabichromene) and progressing our existing programs,” commented Eric A. Adams, InMed President and CEO.

The management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products, in addition to expanding revenues substantially in the short-to-medium term. Further, the integrated science teams will be looking to explore the therapeutic potential of BayMedica’s novel cannabinoid analogs for incorporation into InMed’s pharmaceutical drug development.

With regards to its proprietary IntegraSyn(TM) cannabinoid manufacturing approach, the team is currently focused on process optimization for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) production of rare cannabinoids. InMed holds that IntegraSyn will be a preferred pharmaceutical production method and may fit perfectly with BayMedica’s chemical synthesis and biosynthesis manufacturing approaches for non-pharmaceutical applications.

In addition, September 30 also marked the beginning of the 755-201-EB study, InMed’s Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). The commencement of the study marked the first time cannabinol has advanced to a Phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment. The study, which has ethics and regulatory authority approvals in five countries and is expected to take place across seven countries, namely Austria, Germany, Greece, France, Italy, Israel, and Serbia, follows two completed Phase 1 studies.

The Phase 1 studies strongly evidenced the overall safety and tolerability of the INM-755 cream. In addition, preclinical data showed that the cream might help relieve characteristic EB symptoms, including pain and inflammation, as well as potentially restore the skin’s integrity in some EB Simplex patients.

Combined, the activities related to the INM-755 clinical trials contributed to the company’s increased research and development (“R&D”) expenses for Q1 2022, which stood at $1.5 million, up from $0.9 million in Q1 2021.

InMed has also developed a cannabinol (“CBN”) topical eye drop formulation, INM-088, currently the subject of preclinical studies as a potential treatment for glaucoma. Data from these studies demonstrate CBN’s effectiveness in reducing cell death in retinal ganglion cells, indicating the cannabinoid’s neuroprotective capabilities that may extend vision retention. In addition, preclinical data suggest that CBN reduces intraocular pressure in glaucoma models. On August 17, the company presented at the H.C. Wainwright Ophthalmology Conference detailing these findings.

InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088.

Other key highlights of the report and business update included an international patent application for treating neurodegenerative diseases using rare cannabinoids filed early this month, as well as a notable quarter-over-quarter increase in the company’s cash, cash equivalents, and short-term investments from $7.4 million in Q4 2021 to $15.4 million in Q1 2022. InMed attributed this increase to the July 2 private placement in which the company received net proceeds of approximately $11.0 million.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Schedules November 29th for Q3 2021 Financials Release; November 30th for Earnings Discussion

RWB is set to release its Q3 financial results on November 29, 2021
A conference call will follow this release on November 30, 2021, at 5:00 PM ET to discuss these results, the company’s operations, upcoming events, and a Q&A session
A replay of the call will be available for 90 days, starting three hours after the conclusion
RWB is increasingly optimistic about its Q3 performance following growth in revenue from Q1 to Q2, along with strategic investments that would allow for Q3 growth

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) just announced that it will be releasing its third-quarter (“Q3”) 2021 financial results on Monday, November 29, 2021, after market close. The company will also hold management discussions and analyses (“MD&A”) and other subsequent events following the release (https://nnw.fm/L75Sz).

This will mark Christopher Ecken’s first financial release, having joined RWB as its new Chief Financial Officer (“CFO”) back in October 2021 (https://nnw.fm/xKsci).

A conference call is also scheduled for Tuesday, November 30, 2021, at 5:00 PM ET. Here, Brad Rogers, RWB’s Chief Executive Officer (“CEO”), will introduce Mr. Ecken, after which they will discuss the company’s Q3 2021 results, operations, and upcoming events. The conference will also feature a Q&A session with the company’s management, during which attendees will have the opportunity to ask them questions on various topics, including the company’s Q3 financial performance.

RWB is optimistic about its Q3 performance. During the Q2 2021 announcement back in August 2021, Mr. Rogers was keen to acknowledge that the company was making significant strides that would play an integral role in its Q3 financial performance.

“We continue to make great strides with our branded products and see momentum in Q2, which has teed up Q3 nicely, and will translate into a strong second half,” he noted.

“In Florida, after closing the acquisition at the end of April, we have made strategic investments that are allowing us to quickly ramp up capacity as well as complete construction for new store openings before the end of 2021,” he added (https://nnw.fm/Hu4wJ).

Mr. Rogers announced that revenue for the second quarter was up by 13% from the previous quarter, along with several significant raw material inventory purchases geared towards supporting growth for Q3, in anticipation of new branded product line launches.

Those interested in the announcement can listen online and ask questions via this webcast link:

https://nnw.fm/PW0n6. (Questions during the Q&A will be accepted only via this link.)

Dial-in numbers for the conference call for listening only are:

877-705-6006
201-689-8557

A recording of the call will be available approximately three hours following the conference call at https://ir.redwhitebloom.com/

The call will also be available for replay for 90 days, starting three hours after the conclusion of the call. Simply dial 877-660-6853 or 201-612-7415 and enter access ID: 13725118.

Going forward, RWB will be announcing dates of earnings reports 30 days before their release. This is one of several new operating procedures to be implemented by Christopher Ecken, RWB’s new CFO.

For more information, visit the company’s website at www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://nnw.fm/RWBYF

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

StraightUp Resources Inc.’s (CSE: ST) (OTCQB: STUPF) Exploration and Expansion Program, A 2021 Outlook

StraightUp marked 2021 with strategic opportunities in the United States and Peru
These projects were selected by management based on past exploration and proven reserves in these regions
2021 also marked the year StraightUp up-listed to the OTCQB Venture Market in the United States
StraightUp is optimistic about 2022

For the 2021 fiscal and calendar year, StraightUp Resources (CSE: ST) (OTCQB: STUPF) set out on an aggressive asset acquisition plan, coupled with an exploration program that would be the highlight of the year. Thus far, it has acquired the West Cat Mine in Nevada, along with the Ferdinand Gold Project and Bear Head Gold Project, both located in western Ontario (https://nnw.fm/pRJ5Y). However, these acquisitions do not aptly represent its commitment to maximizing shareholder wealth as its aggressive exploration program.

StraightUp, at the beginning of the year, broke down its 2021 exploration program into four elements:

Historical data review, compilation, and interpretation
Examining historical drill core (ENDM core library, Red Lake)
Geological mapping and sampling
Geophysical surveys

The objective was to add new 2021 data to enhance interpretations, locate prime locations for drilling holes and conduct soil sampling to inform the company’s investment decisions and guarantee a return on its investment. This exploration program was firmly founded on science, mainly SGH soil sampling, primitive-mantle normalized trace element geochemistry, and geophysical surveys, among others (https://nnw.fm/RAjyf).

So far, these efforts have allowed StraightUp to acquire prime properties with tremendous potential to maximize shareholder wealth. It has also allowed the company to expand its market reach, with its entry into the American market with the West Cat Mine acquisition in Nevada and the Peruvian market with the exclusive rights to purchase of the Mallay silver mine.

StraightUp also made a significant move to expand its access to investors by up-listing to the OTCQB Venture Market in the United States (https://nnw.fm/vuton). It comes just in time as the company grows its asset portfolio, opening its doors to millions of investors within the United States, particularly as it plans to execute on its next phase of growth. In addition, the company hopes to benefit shareholders through increased trading liquidity through this move, ultimately adding more value for them and their investment. Over the past year, the company has made some important gains and its management has expressed optimism for the 2022 financial year in growing shareholder value.

For more information, visit the company’s website at www.StraightUpResources.com.

NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://nnw.fm/STUPF

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Produces Raw Materials for Numerous Clean-Energy, Advanced Technologies

An ever-increasing demand for energy is fueling the focus on sustainable energy solutions.
UUUU is proud to produce the raw materials that make numerous clean-energy and advanced technologies possible.
Energy Fuels began producing rare earths in 2021, which are used in electric vehicles, renewable energy, batteries and other technologies.

As the world becomes more focused on and committed to clean energy and sustainability, companies in every sector are recognizing the importance of advancing ESG (environmental, sustainability, and governance) priorities. A leading U.S.-based uranium mining company Energy Fuels (NYSE American: UUUU) (TSX: EFR) places a high priority on its efforts to produce raw materials that support global clean-energy efforts.

“As the world population continues to grow, there is an ever-increasing demand for energy, and renewable sources are the answer to providing sustainable energy solutions, while also protecting the planet from climate change,” states a TWI article. “The take-up of clean energy is not just happening on a national level as cities and states are also creating policies to increase renewable energy use.

“In the United States, 29 states have set renewable energy portfolios to mandate that a certain percentage of energy consumed should come from renewable sources, and over 100 cities around the world now use at least 70% renewable energy,” the article continued. “The most important aspect of clean energy are the environmental benefits as part of a global energy future.

“While clean, renewable resources also preserve the world’s natural resources, they also reduce the risk of environmental disasters, such as fuel spills or the problems associated with natural gas leaks,” the article states. “With fuel diversification, through different power plants using different energy sources, it is possible to create reliable power supplies to enhance energy security, ensuring there is enough to meet our demands.”

With that as a backdrop, Energy Fuels does much more than just product uranium, which is the fuel for nuclear energy, producing 50% of all clean, carbon-free electricity in the U.S. “Energy Fuels is proud to produce the raw materials that make numerous clean energy and advanced technologies possible, all in the U.S. at the highest global standards for health, safety and environmental protection,” noted UUUU president and CEO Mark Chalmers (https://nnw.fm/mWzyx). In addition to producing uranium, the fuel for carbon- and emission-free nuclear energy, UUUU began operations to recover rare earth elements (“REEs”) in 2021, which are used in electric vehicles, renewable energy, batteries and other clean technologies.

Also worth noting is that, in 2019, the company was the largest U.S. producer of vanadium, which is used in steel, high-strength alloys and grid-scale batteries. Finally, in addition to its efforts to produce material, Energy Fuels is committed to preserving global resources and addressing climate change through industry-leading recycling programs.

Not a company to rest on its laurels, Energy Fuels is also exploring other business opportunities, including evaluation the recovery of medical isotopes for use in emerging cancer therapies from existing process streams.

Energy Fuels is the leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and began commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States.

Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year.

In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.